Sustainability Accounting Standards Board (SASB) Index

Code	Metrics	Sanofi's Disclosures	Comments
Safety of Clinical Trial Participants			
HC-BP-210a.1	Discussion, by world region, of management process for ensuring quality and patient safety during clinical trials	• Medical Ethics, Bioethics and Clinical Trials • URD: Chapter 3 p.37 • Bioethics Policies	All our clinical trials are run in accordance with the Principles of Good Clinical Practice (GCP) and international ethical standards, in particular the Helsinki Declaration on ethical principles regarding human experimentation.
HC-BP-210a.2	Number of FDA Sponsor Inspections related to clinical trial management and pharmacovigilance that resulted in: (1) Voluntary Action Indicated (VAI); and (2) Official Action Indicated (OAI)	• URD: Chapter 3 p.39	Sanofi systematically aligns on the most exacting standards of Good Pharmacovigilance Practices. In 2023, 34 audits and 12 inspections have been conducted on Pharmacovigilance.
HC-BP-210a.3	Total amount of monetary losses as a result of legal proceedings associated with clinical trials in developing countries	• Form 20-F p.148	Sanofi and its subsidiaries disclose their involvement in litigation, arbitration and other legal proceedings.
Access to Medicines			
HC-BP-240a.1	Description of actions and initiatives to promote access to health care products for priority diseases and in priority countries as defined by the Access to Medicine Index	• Addressing the Needs of Rare Disease Patients around the World • Access to Vaccines • URD: Chapter 3 p.28 •	Sanofi strives to provide better health and access to quality medicines and vaccines for patients and populations who need them around the world. Sanofi employs an approach adapted to the specifics of both healthcare systems and local needs, through different access models (commercial, social, and philanthropy).

			Sanofi Global Health Unit (GHU) is our non-profit business unit with a remit to increase access to healthcare for patients in 40 of the lowest income countries in the world.
HC-BP-240a.2	List of products on the WHO List of Prequalified Medicinal Products as part of its Prequalification of Medicines Programme (PQP)	• URD: Chapter 3 p.28 •	Sanofi and the World Health Organization (WHO) have joined forces in the fight against NTDs since 2001. The list of medicines and vaccines is available here.
Affordability & Pricing			
HC-BP-240b.1	Number of settlements of Abbreviated New Drug Application (ANDA) litigation that involved payments and/or provisions to delay bringing an authorized generic product to market for a defined time period	• Form 20-F p.148	
HC-BP-240b.2	Percentage change in: (1) average list price and (2) average net price across U.S. product portfolio compared to previous year	• URD: Chapter 3 p. 31 • Prescription Medicine Pricing Principles	
HC-BP-240b.3	Percentage change in: (1) list price and (2) net price of product with largest increase compared to previous year	Not reported	
Drug Safety			
HC-BP-250a.1	List of products listed in the Food and Drug Administration's (FDA) MedWatch	• FDA's MedWatch Safety Alerts for Human Medical Products database • Form 20-F p. F-81	

	Safety Alerts for Human Medical Products database		
HC-BP-250a.2	Number of fatalities associated with products as reported in the FDA Adverse Event Reporting System	• FDA Adverse Event Reporting System	
HC-BP-250a.3	Number of recalls issued, total units recalled	• URD: Chapter 3 p.39	In 2023, Sanofi conducted 25 recalls (40 in 2022 and 38 in 2021).
HC-BP-250a.4	Total amount of product accepted for takeback, reuse, or disposal	• Pharmaceuticals in the environment • URD: Chapter 3 p.66 • Planet Care	Sanofi focuses particular attention on the challenge of preventing pharmaceuticals from entering the environment. Sanofi is committed to minimize the potential environmental impacts of our medicines through its "Planet Care" program.
HC-BP-250a.5	Number of FDA enforcement actions taken in response to violations of current Good Manufacturing Practices (cGMP), by type	• URD: Chapter 3 p.39	In 2023, Sanofi has received 251 regulatory inspections, of which 16 were conducted by the US FDA.
Counterfeit Drugs			
HC-BP-260a.1	Description of methods and technologies used to maintain traceability of products throughout the supply chain and prevent counterfeiting	• URD: Chapter 3 p.41 •	
HC-BP-260a.2	Discussion of process for alerting customers and business partners of potential or known risks associated with counterfeit products	• URD: Chapter 3 p.41	The Sanofi Global Security network supports the implementation of actions to combat falsified medicine and illicit trafficking in liaison with the

			industry, law enforcement, and health authorities. This provides a capacity to detects medicine trafficking globally and to deploy a consistent level of security measures to prevent risks to products and patients.
HC-BP-260a.3	Number of actions that led to raids, seizure, arrests, and/or filing of criminal charges related to counterfeit products	• URD: Chapter 3 p.42	
Ethical Marketing			
HC-BP-270a.1	Total amount of monetary losses as a result of legal proceedings associated with false marketing claims	• Form 20-F p.148	Sanofi and its subsidiaries disclose their involvement in litigation, arbitration and other legal proceedings.
HC-BP-270a.2	Description of code of ethics governing promotion of off-label use of products	• URD: Chapter 3 p.47 • Code of Conduct	The core mission of our promotional activities is to provide quality information about the product presented in compliance with the marketing authorization for that product, and to promote correct use of the product among healthcare professionals.
Employee Recruitment, Development & Retention			
HC-BP-330a.1	Discussion of talent recruitment and retention efforts for scientists and research and development personnel	• URD: Chapter 3 p.13	
HC-BP-330a.2	(1) Voluntary and (2) involuntary turnover rate for:	• URD: Chapter 3 p.13 •	

	(a) executives/senior managers, (b) midlevel managers, (c) professionals, and (d) all others	• ESG Key Performance Indicators	
Supply Chain Management			
HC-BP-430a.1	Percentage of (1) entity's facilities and (2) Tier I suppliers' facilities participating in the Rx-360 International Pharmaceutical Supply Chain Consortium audit program or equivalent third-party audit programs for integrity of supply chain and ingredients	• URD: Chapter 3 p.37-39	For all manufacturing, supply and distribution of our pharmaceutical products and vaccines, our facilities hold the manufacturing licenses and GxP certificates issued by the appropriate health authorities (FDA, EMEA, WHO…)
Business Ethics			
HC-BP-510a.1	Total amount of monetary losses as a result of legal proceedings associated with corruption and bribery	• Form 20-F p.148	Sanofi and its subsidiaries disclose their involvement in litigation, arbitration and other legal proceedings.
HC-BP-510a.2	Description of code of ethics governing interactions with health care professionals	• URD: Chapter 3 p.47 • Form 20-F p.36 • Service Engagements With Scientific Experts • Code of Conduct	
Activity Metric			
HC-BP-000.A	Number of patients treated	• URD: Chapter 3 p.28 • ESG Key Performance Indicators • Vaccines at a Glance	Considering the size of our product portfolio, we do not disclose patient demographic except for specific product, market segment or geographies. For instance, we estimate that half a billion people are vaccinated every year with our vaccines. We also

			track the number of patients reached by our Sanofi Global Health Unit and report on progress in our quarterly results.
HC-BP-000.B	Number of drugs (1) in portfolio and (2) in research and development (Phases 1-3)	• (1) Form 20-F p.18-29 • (2) Research and Development •	

SMART LINKS:

- Sanofi Website
- Document Center
- Annual Report on Form 20-F 2023
- Universal Registration Document (in French)
- Declaration of Extra-Financial Performance (Chapter 3 of the Universal Registration Document)